Tenaya Therapeutics
[stock_market_widget type=”inline-label” template=”indicator” assets=”TNYA” realtime=”true” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”TNYA” fields=”market_cap,enterprise_value,pe_ratio,forward_pe_ratio,peg_ratio,price_to_sales_trailing_12_months,price_book,enterprise_revenue,enterprise_ebitda” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”TNYA” fields=”volume,open,previous_close,range,52_week_range,beta,target_high_price,shares_outstanding,shares_float” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”chart” template=”line” assets=”TNYA” range=”1y” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#000000″ range_selector=”true” axes=”true” cursor=”true” style=”font-size: 14px” api=”yahoo-finance”]
Description
Tenaya Therapeutics is a biotechnology company developing genetic medicines for cardiovascular diseases. Its programs use gene therapy, gene editing, and regenerative approaches to address the underlying causes of heart failure and related disorders.
Financial Highlights
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”TNYA” fields=”profit_margin,operating_margin,return_on_assets,return_on_equity,total_revenue,revenue_per_share,revenue_growth,gross_profit,ebitda,net_income_to_common,quarter_earnings_growth,total_cash,total_cash_per_share,total_debt,operating_cashflow” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
Trading Information
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”TNYA” fields=”52_week_low_change_pct,52_week_high,52_week_low,50_day_average,200_day_average,average_volume,average_volume_10_days,shares_outstanding,shares_float,held_percent_insiders,held_percent_institutions,shares_short,short_ratio,annual_dividend_rate,annual_dividend_yield” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
